key: cord-0684540-8rfarv1o authors: Maramattom, Boby Varkey; Zachariah, Ann Noble; Meleth, Hanna Angel; Zachariah, Zachariah T.; Mathew, K.M. title: Post Covid-19 Guillain Barre Syndrome date: 2021-04-16 journal: Ann Indian Acad Neurol DOI: 10.4103/aian.aian_853_20 sha: bc4d7ee2d0cb02086298ece16426ea139b91d7b9 doc_id: 684540 cord_uid: 8rfarv1o nan Dear Editor, The neurological complications of the present COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 are well documented. [1] As of the 10 th September 2020, the global SARS-CoV2 infections have crossed 27 million with over 4.3 million cases and 73,000 death from India. There are a few reports of neurological complications of COVID-19 from India; however, post-COVID-19 Guillian-Barre Syndrome (GBS) as an immune-mediated phenomenon has not been reported. [2] [3] [4] A 60-year-old man with a history of diabetes and hypertension on treatment was evaluated for cough 2.5 months earlier. Nasal swab RT-PCR was positive for SARS-CoV2. Repeat nasal swab tests were negative on day 16. Nine weeks after his last negative test, he developed left leg weakness and buckling at the knees. Over the next 3 days, he developed an asymmetrical lower limb weakness [Left > right], unsteadiness, and paresthesias of all limbs. On examination, he had grade 4/5 MRC scale power in his upper limbs, 1/5 power in the proximal lower limbs, upper limb ataxia, bifacial weakness, and global areflexia without any sensory signs. CSF study showed an albumin-cytologic dissociation [5 WBC's with elevated protein-187.3 mg/dL]. CSF RT-PCR for SARS-CoV2 was not performed as it was 10-11 weeks after his acute illness. Nerve conduction studies showed absent F waves, prolonged distal latencies, and slowed conduction velocities. His routine blood tests were normal, LDH-311 U/L (125-220, ferritin 88 ng/ml (18.7-323), and serology was non-reactive for HIV, Hepatitis B and C viruses. He was diagnosed to have postinfectious GBS and treated with IVIg at 2 gm/Kg over 5 days along with intensive physiotherapy. Over the next 10 days, he worsened to MRC grade 2/5 power in all limbs with limb ataxia and areflexia. He also developed neck and truncal weakness. By day 19, he started improving [grade 3/5 power]. An MRI whole-body STIR muscle imaging was normal. Serum CPK levels were normal. An EMG on day 19 was essentially normal. On day 22, his serum ganglioside antibody panel testing were also highly reactive [60.3] {Biological reference interval > 1.0}, suggesting a post-COVID convalescent phase. This assay detects high-affinity IgM, IgA, and IgG antibodies which appear in the 2 nd week of illness. It uses an electrochemiluminescence immunoassay analyzer (ECLIA) and is comparable to an EDI ELISA test. [5] By day 27, he was able to sit without support. The incidence of neurological complications in COVID-19 approaches ~ 36% in large series [ Figure 1 ]. [6] Both cranial and peripheral neuropathies [including GBS and Miller Fisher syndrome] have been documented in the acute phase of COVID-19 illness. [7, 8] The neuromuscular complications are linked to direct neural invasion of the coronavirus, infective leptomeningitis or to para or postinfectious immune-mediated phenomena. Most reports of GBS in COVID-19 is documented with acute SARS-CoV2 infection. Most patients have presented in the acute phase of the illness with a mean period of ~ 11 days from the onset of acute viral illness. [9] In some patients, GBS alone without any other symptoms has been the presenting manifestation of COVID-19. COVID-GBS cases were similar to non-COVID-19 GBS, showing a demyelinating pattern on electrophysiological studies, albumino-cytologic dissociation in the CSF and negative for SARS-CoV-2 RT-PCR on CSF. [10] Tested sera were negative for serum anti-ganglioside antibodies in most patients. Like our patient, a few cases showed serum anti-GD1b ganglioside antibodies with Miller-Fisher syndrome. Most reports have shown a consistent response to intravenous immunoglobulin or plasma exchange with improvement within 8 weeks in the majority. The vast majority of reports of GBS with COVID-19 have been para-infectious and post-infectious GBS is rare. [11, 12] As experts have predicted an uptick in post-infectious immune-mediated neurological complications after the peak of the pandemic, our report is noteworthy in its documentation of a post-COVID-19 GBS. To the best of our knowledge, this is the first report of a post-COVID-19 immune-mediated neurological disorder from India. Nil. Neurological complications of Covid-19. A contemporaneous review Covid-19-associated acute haemorrhagic leukoencephalomyelitis SARS-CoV-2-associated Acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: A case report Guillain-Barré syndrome following COVID-19: New infection, old complication? Comparison of the Elecsys Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma Neurologic manifestations of hospitalized patients with Coronavirus disease Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection COVID-19-Associated Guillain-Barre syndrome: The early pandemic experience Guillain-Barré syndrome related to COVID-19 infection Guillain-Barré syndrome associated with SARS-CoV-2 Guillain-Barré syndrome associated with SARS-CoV-2 infection